Artisan Partners Limited Partnership Argenx Se Transaction History

Artisan Partners Limited Partnership

$58.2 Billion
Q1 2025

A detailed history of Artisan Partners Limited Partnership transactions in Argenx Se stock. As of the latest transaction made, Artisan Partners Limited Partnership holds 2,785,890 shares of ARGX stock, worth $1.56 Billion. This represents 2.84% of its overall portfolio holdings.

Number of Shares

2,785,890

Previous 3,069,995 9.25%

Holding current value

$1.56 Billion

Previous $1.89 Billion 12.67%

% of portfolio

2.84%

Previous 3.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$571.0 - $671.75 $162 Million - $191 Million	-284,105 Reduced 9.25%	2,785,890 $1.65 Billion
Q4 2024 Feb 12, 2025	SELL	$520.52 - $638.33 $231 Million - $283 Million	-443,247 Reduced 12.62%	3,069,995 $1.89 Billion
Q3 2024 Nov 12, 2024	BUY	$434.22 - $551.9 $939,652 - $1.19 Million	2,164 Added 0.06%	3,513,242 $1.91 Billion
Q2 2024 Aug 12, 2024	BUY	$356.01 - $451.55 $114 Million - $145 Million	321,478 Added 10.08%	3,511,078 $1.51 Billion
Q1 2024 May 13, 2024	BUY	$356.95 - $413.29 $5.4 Million - $6.25 Million	15,123 Added 0.48%	3,189,600 $1.26 Billion
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $117 Million - $175 Million	346,178 Added 12.24%	3,174,477 $1.21 Billion
Q3 2023 Nov 09, 2023	SELL	$369.35 - $548.43 $77.6 Million - $115 Million	-210,084 Reduced 6.91%	2,828,299 $1.39 Billion
Q2 2023 Aug 10, 2023	BUY	$360.14 - $422.58 $2.22 Million - $2.6 Million	6,155 Added 0.2%	3,038,383 $1.18 Billion
Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $139 Million - $168 Million	416,813 Added 15.94%	3,032,228 $1.13 Billion
Q4 2022 Feb 10, 2023	SELL	$342.17 - $402.31 $73 Million - $85.8 Million	-213,283 Reduced 7.54%	2,615,415 $991 Million
Q3 2022 Nov 10, 2022	SELL	$343.2 - $395.75 $71.8 Million - $82.8 Million	-209,217 Reduced 6.89%	2,828,698 $999 Million
Q2 2022 Aug 12, 2022	SELL	$269.58 - $378.88 $85.8 Million - $121 Million	-318,325 Reduced 9.48%	3,037,915 $1.15 Billion
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $44.7 Million - $61.6 Million	175,575 Added 5.52%	3,356,240 $1.06 Billion
Q4 2021 Feb 11, 2022	BUY	$272.01 - $353.03 $84.5 Million - $110 Million	310,573 Added 10.82%	3,180,665 $1.11 Billion
Q3 2021 Nov 12, 2021	SELL	$295.0 - $350.58 $24.2 Million - $28.8 Million	-82,111 Reduced 2.78%	2,870,092 $867 Million
Q2 2021 Aug 12, 2021	BUY	$257.11 - $319.92 $20.6 Million - $25.7 Million	80,214 Added 2.79%	2,952,203 $889 Million
Q1 2021 May 11, 2021	BUY	$268.3 - $380.31 $145 Million - $206 Million	540,488 Added 23.18%	2,871,989 $791 Million
Q4 2020 Feb 10, 2021	BUY	$248.13 - $308.36 $113 Million - $140 Million	454,976 Added 24.25%	2,331,501 $686 Million
Q3 2020 Nov 12, 2020	BUY	$215.51 - $272.51 $42.1 Million - $53.3 Million	195,428 Added 11.63%	1,876,525 $493 Million
Q2 2020 Aug 12, 2020	BUY	$127.44 - $232.72 $21 Million - $38.3 Million	164,406 Added 10.84%	1,681,097 $379 Million
Q1 2020 May 12, 2020	BUY	$108.83 - $165.23 $21.6 Million - $32.8 Million	198,338 Added 15.04%	1,516,691 $200 Million
Q4 2019 Feb 12, 2020	BUY	$106.59 - $164.21 $3.88 Million - $5.98 Million	36,439 Added 2.84%	1,318,353 $212 Million
Q3 2019 Nov 12, 2019	BUY	$113.31 - $150.51 $15.9 Million - $21.1 Million	140,417 Added 12.3%	1,281,914 $146 Million
Q2 2019 Aug 09, 2019	BUY	$115.0 - $141.58 $42.7 Million - $52.5 Million	371,161 Added 48.18%	1,141,497 $162 Million
Q1 2019 May 10, 2019	BUY	$98.85 - $134.59 $44.9 Million - $61.1 Million	454,046 Added 143.55%	770,336 $96.2 Million
Q4 2018 Feb 12, 2019	BUY	$63.81 - $109.82 $5.33 Million - $9.17 Million	83,482 Added 35.86%	316,290 $30.4 Million
Q3 2018 Nov 13, 2018	BUY	$75.5 - $96.63 $17.6 Million - $22.5 Million	232,808 New	232,808 $17.7 Million

Others Institutions Holding ARGX

# of Institutions

499

Shares Held

28.3M

Call Options Held

330K

Put Options Held

286K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.1B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Artisan Partners Limited Partnership with notifications on news.

Account

Artisan Partners Limited Partnership Argenx Se Transaction History